Barrington Research Forecasts Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Investment analysts at Barrington Research issued their Q3 2025 earnings per share estimates for Surmodics in a research report issued to clients and investors on Thursday, May 1st. Barrington Research analyst M. Petusky forecasts that the company will earn ($0.21) per share for the quarter. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.57) EPS, Q1 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.09) EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The firm had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

A number of other brokerages have also issued reports on SRDX. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. StockNews.com initiated coverage on shares of Surmodics in a report on Monday, February 3rd. They set a "hold" rating for the company. Finally, Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $43.00.

Surmodics Price Performance

Shares of SRDX stock opened at $27.64 on Monday. The stock has a 50 day moving average price of $29.43 and a 200 day moving average price of $34.86. The firm has a market capitalization of $395.14 million, a P/E ratio of -27.37 and a beta of 1.30. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44.

Institutional Trading of Surmodics

A number of hedge funds have recently added to or reduced their stakes in SRDX. Hudson Bay Capital Management LP bought a new stake in shares of Surmodics in the 4th quarter valued at about $11,880,000. Bardin Hill Management Partners LP bought a new position in Surmodics in the fourth quarter worth approximately $7,440,000. Eisler Capital Management Ltd. purchased a new stake in Surmodics during the fourth quarter worth $5,394,000. Balyasny Asset Management L.P. bought a new stake in Surmodics during the 4th quarter valued at $4,921,000. Finally, Squarepoint Ops LLC boosted its position in Surmodics by 154.9% during the 4th quarter. Squarepoint Ops LLC now owns 162,066 shares of the company's stock valued at $6,418,000 after acquiring an additional 98,489 shares in the last quarter. 96.63% of the stock is owned by hedge funds and other institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.